JP2023528087A5 - - Google Patents
Info
- Publication number
- JP2023528087A5 JP2023528087A5 JP2022575399A JP2022575399A JP2023528087A5 JP 2023528087 A5 JP2023528087 A5 JP 2023528087A5 JP 2022575399 A JP2022575399 A JP 2022575399A JP 2022575399 A JP2022575399 A JP 2022575399A JP 2023528087 A5 JP2023528087 A5 JP 2023528087A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- deficiency
- fibrosis
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008598.1A GB202008598D0 (en) | 2020-06-08 | 2020-06-08 | Novel compounds |
| GB2008598.1 | 2020-06-08 | ||
| GB2016758.1 | 2020-10-22 | ||
| GBGB2016758.1A GB202016758D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
| PCT/EP2021/065112 WO2021249909A1 (en) | 2020-06-08 | 2021-06-07 | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528087A JP2023528087A (ja) | 2023-07-03 |
| JP2023528087A5 true JP2023528087A5 (https=) | 2024-06-14 |
Family
ID=76444375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575399A Pending JP2023528087A (ja) | 2020-06-08 | 2021-06-07 | ミトコンドリア機能不全、癌、及び線維症の治療に使用されるＵＳＰ３０阻害剤としての１－（５－（２－シアノピリジン－４－イル）オキサゾール－２－カルボニル）－４－メチルヘキサヒドロピロロ［３，４－ｂ］ピロール－５（１Ｈ）－カルボニトリル |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230312580A1 (https=) |
| EP (1) | EP4161929B1 (https=) |
| JP (1) | JP2023528087A (https=) |
| KR (1) | KR20230022215A (https=) |
| CN (1) | CN115836073B (https=) |
| AU (1) | AU2021286831A1 (https=) |
| BR (1) | BR112022024794A2 (https=) |
| CA (1) | CA3186148A1 (https=) |
| CO (1) | CO2022017233A2 (https=) |
| DK (1) | DK4161929T3 (https=) |
| ES (1) | ES3040433T3 (https=) |
| FI (1) | FI4161929T3 (https=) |
| HR (1) | HRP20250891T1 (https=) |
| HU (1) | HUE072598T2 (https=) |
| IL (1) | IL298785B2 (https=) |
| LT (1) | LT4161929T (https=) |
| MD (1) | MD4161929T2 (https=) |
| MX (1) | MX2022015608A (https=) |
| PL (1) | PL4161929T3 (https=) |
| PT (1) | PT4161929T (https=) |
| RS (1) | RS67140B1 (https=) |
| SI (1) | SI4161929T1 (https=) |
| SM (1) | SMT202500343T1 (https=) |
| WO (1) | WO2021249909A1 (https=) |
| ZA (1) | ZA202213877B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4161929T3 (da) * | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129371A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129365A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| DK4161929T3 (da) * | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
-
2021
- 2021-06-07 DK DK21732212.2T patent/DK4161929T3/da active
- 2021-06-07 AU AU2021286831A patent/AU2021286831A1/en active Pending
- 2021-06-07 ES ES21732212T patent/ES3040433T3/es active Active
- 2021-06-07 WO PCT/EP2021/065112 patent/WO2021249909A1/en not_active Ceased
- 2021-06-07 MD MDE20230409T patent/MD4161929T2/ro unknown
- 2021-06-07 HR HRP20250891TT patent/HRP20250891T1/hr unknown
- 2021-06-07 US US18/008,352 patent/US20230312580A1/en active Pending
- 2021-06-07 KR KR1020237000509A patent/KR20230022215A/ko active Pending
- 2021-06-07 CN CN202180040683.1A patent/CN115836073B/zh active Active
- 2021-06-07 BR BR112022024794A patent/BR112022024794A2/pt unknown
- 2021-06-07 JP JP2022575399A patent/JP2023528087A/ja active Pending
- 2021-06-07 SI SI202130328T patent/SI4161929T1/sl unknown
- 2021-06-07 EP EP21732212.2A patent/EP4161929B1/en active Active
- 2021-06-07 LT LTEPPCT/EP2021/065112T patent/LT4161929T/lt unknown
- 2021-06-07 IL IL298785A patent/IL298785B2/en unknown
- 2021-06-07 FI FIEP21732212.2T patent/FI4161929T3/fi active
- 2021-06-07 PT PT217322122T patent/PT4161929T/pt unknown
- 2021-06-07 PL PL21732212.2T patent/PL4161929T3/pl unknown
- 2021-06-07 RS RS20250744A patent/RS67140B1/sr unknown
- 2021-06-07 MX MX2022015608A patent/MX2022015608A/es unknown
- 2021-06-07 HU HUE21732212A patent/HUE072598T2/hu unknown
- 2021-06-07 SM SM20250343T patent/SMT202500343T1/it unknown
- 2021-06-07 CA CA3186148A patent/CA3186148A1/en active Pending
-
2022
- 2022-11-30 CO CONC2022/0017233A patent/CO2022017233A2/es unknown
- 2022-12-21 ZA ZA2022/13877A patent/ZA202213877B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528087A5 (https=) | ||
| JP2022546717A5 (https=) | ||
| JP2023527025A5 (https=) | ||
| HRP20250891T1 (hr) | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze | |
| AP813A (en) | Urea derivatives as inhibitors of IMPDH enzyme. | |
| JP2019533659A5 (https=) | ||
| JP2023529570A5 (https=) | ||
| JP6577623B2 (ja) | グルタミナーゼのヘテロ環式阻害剤 | |
| JP6059255B2 (ja) | ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法 | |
| JP2019532950A5 (https=) | ||
| JP2019532945A5 (https=) | ||
| ES2364959T3 (es) | Agentes antibacterianos. | |
| CA2905340C (en) | Low dose oral formulations of acebilustat | |
| FR2775187A1 (fr) | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo | |
| JP2020524166A5 (https=) | ||
| JP2012524055A5 (https=) | ||
| EP3066077A1 (en) | Treatment of cardiac remodeling and other heart conditions | |
| US20250120926A1 (en) | Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent | |
| JP2022068371A (ja) | ＲＮＡｉ分子とＮ－アセチル化キトサンとを含む複合体 | |
| JP2024544660A5 (https=) | ||
| WO2007086012A1 (en) | Formulation of cefpodoxime, clavulanic acid and linezolid | |
| WO2010120253A1 (en) | Thiocolchicoside and non-steroidal anti-inflammatory drug combinations | |
| ITMI20131906A1 (it) | Composizioni solide orali a lento rilascio | |
| JP7805288B2 (ja) | 操作された細胞及びその使用 | |
| WO2013079205A1 (en) | Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) |